Noa G. Holtzman, M.D.

Noa G. Holtzman, M.D.

  • Center for Cancer Research
  • National Cancer Institute
Immune Deficiency Cellular Therapy Program


Dr. Holtzman's main research interests include hematopoietic stem cell transplantation (HSCT) for hematologic malignancies with a focus on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), graft-versus-host disease (GVHD), improving post-transplant outcomes, and cellular immunotherapy.

Areas of Expertise

1) hematopoietic stem cell transplantation 2) graft-versus-host disease 3) hematologic malignancies 4) myelodysplastic syndromes 5) acute myeloid leukemia 6) cellular therapy

Information for Patients

Learn more about our clinical trials and the highly specialized care teams that lead them.


Selected Recent Publications

Immune Effector Cell- Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T-cell Therapy for Lymphoma: Predictive Biomarkers and Clinical Outcomes

Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S.
Neuro Oncol. Epub ahead of print (Aug. 5), 2020. [ Journal Article ]

Clinical characteristics and cytokine biomarkers in patients with chronic graft-vs-host disease persisting seven or more years after diagnosis

Goklemez S, Im AP, Cao L, Pirsl F, Steinberg SM, Curtis LM, Mitchell SA, Cowen EW, Baruffaldi J, Rose J, Mays J, Ostojic A, Holtzman NG, Hakim FT, Pavletic SZ.
Am J Hematol. Epub ahead of print (Jan. 5), 2020. [ Journal Article ]

Peripheral blood blast rate of clearance is an independent predictor of clinical response and outcomes in acute myeloid leukaemia

Holtzman NG, El Chaer F, Baer MR, Ali O, Patel A, Duong VH, Sausville EA, Singh ZN, Koka R, Zou YS, Etemadi A, Emadi A.
Br J Haematol. 188(6): 881-887, 2020. [ Journal Article ]

Refractory postallogeneic stem cell transplant pure red cell aplasia in remission after treatment with daratumumab

Bathini S, Holtzman NG, Koka R, Singh Z, Wilding E, Zou Y, Ruehle K, Kocoglu MH, Badros A, Hardy N, Yared J, Rapoport AP, Fontaine M, Emadi A, El Chaer F, Dahiya S.
Am J Hematol. 94(8): E216-E219, 2019. [ Journal Article ]

Genomics trumps clinical criteria in BMT? Nyet!

Holtzman NG, Rapoport AP.
Blood. 129(17): 2335-2336, 2017. [ Journal Article ]